{"id":"ab103","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, AB103 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"AB103 is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:09.396Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT03403751","phase":"PHASE3","title":"Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury","status":"TERMINATED","sponsor":"Atox Bio Ltd","startDate":"2018-05-24","conditions":"Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection","enrollment":58},{"nctId":"NCT02469857","phase":"PHASE3","title":"Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections","status":"COMPLETED","sponsor":"Atox Bio Ltd","startDate":"2015-12-01","conditions":"Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene","enrollment":290},{"nctId":"NCT01417780","phase":"PHASE2","title":"Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients","status":"COMPLETED","sponsor":"Atox Bio Ltd","startDate":"2011-12","conditions":"Necrotizing Soft Tissue Infections","enrollment":43},{"nctId":"NCT01166984","phase":"PHASE1","title":"AB103 Peptide Antagonist in Healthy Volunteers","status":"COMPLETED","sponsor":"Atox Bio Ltd","startDate":"2010-09","conditions":"Healthy Volunteer Safety Study","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["p2TA"],"phase":"phase_2","status":"active","brandName":"AB103","genericName":"AB103","companyName":"Atox Bio Ltd","companyId":"atox-bio-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AB103 is a monoclonal antibody targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}